Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- Conclusion of TPP Talks over IP Rights Postponed
October 29, 2013
- Kenporen Calls for Taking 6 APIs Over the Counter
October 29, 2013
- LDP Establishes Study Group on Pharmaceutical Industry Policy; 11 Domestic Drug Makers to Participate
October 28, 2013
- TPP IP Talks Kick Off in Tokyo, Government Task Force to Hold Press Conference on Oct 28
October 25, 2013
- Regulatory Reform Council to Convene Public Discussion on Expansion of “Mixed Healthcare” on November 28
October 25, 2013
- Diovan Panel Should Question 4 Key Figures to Dig into Scandal Further: Expert Member
October 24, 2013
- Lawmakers Concerned over Effects of Diovan Papers on Public Finances for Health Insurance
October 24, 2013
- Probable Price Settlement Rate of Lower 70% Range “Disappointing”: MHLW’s Economic Affairs Head Jo
October 24, 2013
- PFSB Notification Calls for Revisions to Precautions Sections of Package Inserts for Olmesartan and Other Drugs
October 24, 2013
- MOF Demands Hefty Price Cuts for Long-Listed Products, Skeptical about Premium
October 23, 2013
- Govt Task Force Briefs Trade Groups on Tokyo’s Hosting of TPP Interim Talks on IP
October 23, 2013
- Basic Policy Calls for Wider Range of Uninsured Healthcare Services in National Strategic Special Zones
October 23, 2013
- Expert Panel Calls for Measures to Promote Commercialization of Results of Basic Research in Field of Healthcare
October 23, 2013
- DPJ Nagatsuma Requests Summoning Novartis President and Former Employee for Unsworn Diet Testimony
October 22, 2013
- Avastin to Receive Additional Indication for Ovarian Cancer: PAFSC’s Second Committee on Drugs
October 22, 2013
- Vaccine Policy Committee Agrees on Draft of Basic Vaccination Plan
October 22, 2013
- 72 Face-to-Face Consultations Provided from July 2011 through September 2013: PMDA
October 21, 2013
- Ex-Health Minister Nagatsuma Eyes Unsworn Diet Testimony by Ex-Novartis Employee on Diovan Scandal
October 18, 2013
- CSIMC’s Bill Payer, Industry Reps at Odds over Objective of Premium; “Elimination of Drug Lag” vs. “New Drug Development”
October 18, 2013
- 1st Committee on Drugs to Discuss Approval for JT’s Hyperphosphatemia Treatment on October 28
October 18, 2013
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…